Update following Attana’s participation at Swiss Nordic Bio and Biotech Showcase™
Earlier this year, Attana participated in the conferences Swiss Nordic Bio and Biotech Showcase™ to present the company and participate in meetings with potential customers, strategic partners and investors. The conferences took place digitally and involved both Swedish and international actors.
Attana experienced a strong interest in the company and the presentations that were held. In addition, the company also participated in several virtual meetings with other interesting participants. The conferences have led to dialogues being initiated with potential customers for contract research and instrument sales, as well as with partners for the company's efforts within diagnostics.
For more information, please contact:
Teodor Aastrup, CEO Attana AB
+ 46 8 674 57 00
The Board of directors for Attana consider that the information in this press release is not likely to have a significant effect on the share price but is of general interest for the shareholders and hence should be communicated.
Attana was founded in 2002 with the vision of in vitro characterization of molecular interactions mimicking in vivo conditions. Since then, Attana has developed proprietary label free biosensors for biochemical, crude, sera, and cell-based assays and the Attana Virus Analytics (AVA) platform, a proprietary in vitro diagnostics (IVD) tool. Attana products and research services are used by Big Pharma, biotech companies and academic institutions within the life sciences. To learn more about our latest services and products, please visit www.attana.com or contact firstname.lastname@example.org